Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Harvard Business School
McKesson
Express Scripts
Boehringer Ingelheim

Last Updated: December 4, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR INSULIN GLARGINE; LIXISENATIDE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for insulin glargine; lixisenatide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00975286 ↗ 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine Completed Sanofi Phase 3 2009-10-01 The purpose of the study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to insulin glargine and metformin with or without thiazolidinediones (TZDs), over a period of 24 weeks of treatment. The primary objective is to assess the effects of lixisenatide in comparison to placebo, when added to insulin glargine and metformin, on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24. The secondary objectives are to assess the effects of lixisenatide on the percentage of patients reaching HbA1c less than (<) 7 percent (%) and less than or equal to (<=) 6.5%, plasma glucose (fasting, postprandial during a standardized meal challenge test, 7-point self monitored profiles), body weight, insulin glargine doses, to evaluate safety and tolerability (including anti-lixisenatide antibody assessment), and to assess the impact on treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire (state) (DTSQs) in the participating countries where it is validated.
NCT01146678 ↗ Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1 Completed Sanofi Phase 1 2010-06-01 Primary Objective: - to assess the relative bioavailability of a single dose of insulin glargine (Lantus) and lixisenatide given subcutaneously as on-site mix versus separate and simultaneous injections of each drug Secondary Objectives: - to compare the activity of a single dose of insulin glargine and lixisenatide given subcutaneously as on-site mix versus separate and simultaneous injections of each drug - to assess the safety and tolerability of insulin glargine and lixisenatide given subcutaneously as on-site mix
NCT01476475 ↗ Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients Completed Sanofi Phase 2 2011-11-01 Primary Objective: - The purpose of this study was to compare insulin glargine/ lixisenatide fixed ratio combination (FRC) versus insulin glargine on glycemic control over 24 weeks, as evaluated by glycosylated hemoglobin (HbA1c) reduction in type 2 diabetic participants treated with metformin. Secondary Objectives: - To compare insulin glargine/lixisenatide FRC versus insulin glargine over 24 weeks on: - Glycemic control in relation to a meal as evaluated by post-prandial plasma glucose and glucose excursions during a standardized meal test; - Percentage of participants reaching HbA1c <7% or ≤6.5%; - 7-point Self-Monitored Plasma Glucose (SMPG) profile; - Body weight; - Insulin glargine dose - Fasting Plasma Glucose (FPG); - Percentage of participants requiring rescue therapy during the 24-week open label treatment period; - To assess safety and tolerability of insulin glargine/lixisenatide FRC.
NCT01596504 ↗ Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin Completed Sanofi Phase 2 2012-05-01 Primary Objective: - To investigate the effects of repeated subcutaneous doses of lixisenatide 20 μg once daily (QD) as compared to liraglutide 1.2 mg QD or 1.8 mg QD in reducing post-prandial plasma glucose (PPG) assessed as area under the plasma glucose-concentration-time curve (AUC) after a standardized breakfast at the end of a 8-week treatment period in participants with type 2 diabetes mellitus (T2DM) not adequately controlled with insulin glargine (± metformin). Secondary Objectives: - To assess the effects of lixisenatide 20 μg QD as compared to liraglutide 1.2 QD or 1.8 mg QD after an 8-week treatment period in participants with T2DM not adequately controlled with insulin glargine (± metformin) on: - Post-prandial C-peptide, glucagon and appetite perceptions after a standardized breakfast, - Appetite perceptions after standardized dinner, - Gastric emptying after a standardized labelled test meal, - Fasting plasma glucose, 24-hour plasma glucose profile, - Glycosylated hemoglobin (HbA1c), - Insulin glargine dose, - 7-point self monitored plasma glucose (SMPG), - Body weight and waist circumference, - 24-hour heart rate and blood pressure, - To assess lixisenatide and liraglutide safety and tolerability as add on treatment to insulin glargine (± metformin).
NCT01768559 ↗ Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients Completed Sanofi Phase 3 2013-01-01 Primary Objective: - To compare lixisenatide versus insulin glulisine in terms of glycosylated hemoglobin (HbA1c) reduction and body weight change at Week 26 in type 2 diabetic participants not adequately controlled on insulin glargine ± metformin. Secondary Objectives: - To compare the treatments/regimens on: - The percentage of participants reaching the target of HbA1c <7% or ≤6.5%, - Body weight, - Self-Monitored Glucose profiles, - Fasting Plasma Glucose (FPG), - Post-prandial plasma glucose (PPG) /glucose excursions during a standardized meal test (subset of participants), - Daily doses of insulins, - Safety and tolerability.
NCT01910194 ↗ Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying Completed Sanofi Phase 2 2013-12-01 Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
NCT01910194 ↗ Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying Completed Profil Institut für Stoffwechselforschung GmbH Phase 2 2013-12-01 Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for insulin glargine; lixisenatide

Condition Name

Condition Name for insulin glargine; lixisenatide
Intervention Trials
Type 2 Diabetes Mellitus 15
Type 2 Diabetes 3
Diabetes Mellitus 2
Diabetes Mellitus, Type 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for insulin glargine; lixisenatide
Intervention Trials
Diabetes Mellitus 20
Diabetes Mellitus, Type 2 19
Diabetes Mellitus, Type 1 1
Hyperglycemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for insulin glargine; lixisenatide

Trials by Country

Trials by Country for insulin glargine; lixisenatide
Location Trials
United States 151
Germany 9
Romania 6
Canada 6
Mexico 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for insulin glargine; lixisenatide
Location Trials
Texas 6
Maryland 6
California 6
Pennsylvania 6
Michigan 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for insulin glargine; lixisenatide

Clinical Trial Phase

Clinical Trial Phase for insulin glargine; lixisenatide
Clinical Trial Phase Trials
Phase 4 4
Phase 3 13
Phase 2 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for insulin glargine; lixisenatide
Clinical Trial Phase Trials
Completed 20
Active, not recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for insulin glargine; lixisenatide

Sponsor Name

Sponsor Name for insulin glargine; lixisenatide
Sponsor Trials
Sanofi 18
Profil Institut für Stoffwechselforschung GmbH 1
Medical University of Vienna 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for insulin glargine; lixisenatide
Sponsor Trials
Industry 19
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Dow
Colorcon
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.